At this later stage, IL-1 and inflammasome are often considered to be tumor suppressors and several clinical studies for the treatment of cancer patients by either IL-1 mono- or combination therapy with, for example, immune checkpoint inhibitors [50,87,93] are ongoing. This evidence concerns the gene IL1B and neoplasm.